| Name | SP-100030 |
| Description | SP-100030 is a dual inhibitor of NF-κB and activator protein-1 (AP-1), demonstrating potent inhibition with IC50 values of 50 nM for both. It effectively reduces the production of IL-2, IL-8, and TNF-alpha in Jurkat and other T cell lines. Additionally, SP-100030 has been shown to decrease the severity of murine collagen-induced arthritis (CIA). |
| In vitro | SP-100030 blocks the production of IL-2 and IL-8 in Jurkat T-cells at the same concentrations as seen in the luciferase assay (IC50≈30 nM)[1]. ELISA and RT-PCR confirmed that IL-2, IL-8, and TNF-alpha production by activated Jurkat and other T cell lines were inhibited by SP100030[2]. |
| In vivo | SP100030 (10 mg/kg/day; i.p.; day 21 to day 34) significantly decreased arthritis severity[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (114.25 mM), Sonication is recommended.
|
| Keywords | SP-100030 | NF-κB | NFκB | NF-kB | NFkB |
| Inhibitors Related | Undecane | Sodium propionate | Ethyl palmitate | Kojic acid | Uridine | Fumaric acid | Methylamine HCl | 1,4-Naphthoquinone | Glucosamine | Ethyl linoleate | N,N-Dimethylacetamide | Magnesium sulfate |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | NF-κB Signaling Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Antidepressant Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Transcription Factor-Targeted Compound Library |
United States
